AbbVie snags surprise PBAC win

Posted 15 November 2021 AM

Sanofi's blockbuster eczema treatment Dupixent is likely to soon have a new competitor with AbbVie's Rinvoq gaining an unheralded PBAC recommendation, after being deferred at the July meeting - the win, surprisingly revealed in the latest public summary documents. (PSDs).

The company had been seeking approval for a new indication for its blockbuster drug in the treatment of Severe Atopic Dermatitis but the decision was deferred because a TGA Delegate's Overview was not available at the time of consideration.

To see the whole article, please login